Satellos Bioscience (NASDAQ:MSLE) Research Coverage Started at Craig Hallum

Craig Hallum started coverage on shares of Satellos Bioscience (NASDAQ:MSLE) in a research note issued to investors on Thursday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $24.00 target price on the stock.

A number of other research firms also recently weighed in on MSLE. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Satellos Bioscience in a report on Monday, August 17th. Wells Fargo & Company set a $18.00 target price on Satellos Bioscience in a research note on Thursday, July 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Friday, August 7th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Satellos Bioscience presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.60.

Satellos Bioscience Price Performance

Shares of NASDAQ MSLE opened at $7.49 on Thursday. Satellos Bioscience has a 1 year low of $5.30 and a 1 year high of $13.39. The company’s 50-day moving average is $9.23 and its 200 day moving average is $7.98. The stock has a market capitalization of $158.94 million, a P/E ratio of -3.90 and a beta of 1.51.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). Research analysts anticipate that Satellos Bioscience will post -1.86 earnings per share for the current year.

Hedge Funds Weigh In On Satellos Bioscience

An institutional investor recently raised its position in Satellos Bioscience stock. Stonepine Capital Management LLC increased its position in Satellos Bioscience Inc. (NASDAQ:MSLE) by 391.6% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 491,624 shares of the company’s stock after purchasing an additional 391,624 shares during the period. Satellos Bioscience makes up approximately 0.0% of Stonepine Capital Management LLC’s holdings, making the stock its 16th biggest position. Stonepine Capital Management LLC owned 2.36% of Satellos Bioscience worth $3,723,291 at the end of the most recent reporting period.

About Satellos Bioscience

Satellos Bioscience Corporation (NASDAQ:MSLE) is a biotechnology company focused on developing therapies that promote the natural regeneration and repair of skeletal muscle. Its research is based on the role of muscle stem cells, also known as satellite cells, in maintaining and rebuilding muscle tissue after injury or disease.

The company’s lead program is SAT-3247, an investigational small-molecule therapy being developed for muscle-wasting disorders, including Duchenne muscular dystrophy.